These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 29464665)

  • 1. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
    Di Paolo A; Arrigoni E
    Drugs; 2018 Mar; 78(4):399-410. PubMed ID: 29464665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
    Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
    Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
    Guan X; Zhang J; Man C; Ni B; Shi L
    J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.
    Padula WV; Parasrampuria S; Socal MP; Conti RM; Anderson GF
    Pharmacoeconomics; 2020 Oct; 38(10):1115-1121. PubMed ID: 32533523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
    Socal MP; Parasrampuria S; Anderson GF
    Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of generics in transplantation: Towards rational and safe solutions!].
    Rottembourg J; Rostoker G
    Presse Med; 2018 Mar; 47(3):199-210. PubMed ID: 29555162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
    Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
    Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solution-driven approaches to generic substitution challenges - a survey among international experts.
    Drozdowska A; Hermanowski T
    Fundam Clin Pharmacol; 2015 Dec; 29(6):592-603. PubMed ID: 26214281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia's perspective.
    Alakeel YS; Rampakakis E; AlRumaih A; AlRuwaisan R; Abushal M; AlDalaan AM; Idrees MM; Alanazi ZD; AlKoait H; Muaadi A; AlAfra MAM; AlShaya SA; AlHomida S
    Front Pharmacol; 2024; 15():1376009. PubMed ID: 38698816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Orphan drugs : New opportunities for the treatment of rare diseases].
    Beck M
    Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.